N
SWTX

Natixis’s SpringWorks Therapeutics SWTX Stock Holding History

Natixis’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-63,800
Closed -$2.33M – 1221
2023
Q4 		$2.33M Buy
+63,800
New +$1.67M 0.02% 394
2022
Q2 		– Sell
-95,000
Closed -$5.36M – 1356
2022
Q1 		$5.36M Buy
+95,000
New +$5.44M 0.02% 537
2021
Q4 		– Sell
-33,400
Closed -$2.12M – 1350
2021
Q3 		$2.12M Buy
+33,400
New +$2.57M 0.01% 715
2021
Q2 		– Sell
-35,800
Closed -$2.63M – 1013
2021
Q1 		$2.63M Sell
35,800
-30,600
-46% -$2.4M 0.01% 632
2020
Q4 		$4.82M Buy
+66,400
New +$4.27M 0.02% 519

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Natixis's SWTX Position: Q1 2024 in Review

Natixis sold out of SpringWorks Therapeutics (SWTX) in Q1 2024, closing a stake of 63,800 shares — an estimated $2.33M sold.

Natixis first reported a position in SWTX in Q4 2020 and held it in 5 quarters. The position peaked at $5.36M in Q1 2022. 217 funds tracked by Wall St. Rank hold SWTX as of Q1 2024.

  • Natixis reported no remaining SpringWorks Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 63,800 SpringWorks Therapeutics shares in Q1 2024, an estimated $2.33M.
  • Natixis first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 5 quarters.
  • Natixis's SpringWorks Therapeutics position peaked at $5.36M in Q1 2022.
  • 217 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.